Retrospective Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Jun 28, 2020; 26(24): 3472-3483
Published online Jun 28, 2020. doi: 10.3748/wjg.v26.i24.3472
Table 1 Baseline clinical characteristics of the patients in the two groups
CharacteristicTIPS group (n = 37)Conservative treatment group (n = 17)P value
Gender (male/female)28/911/60.403
Age (yr)62.30 ± 10.9160.18 ± 15.370.563
Onset-to-treatment time (d)28.57 ± 15.2626.18 ± 12.440.535
MELD score12.13 ± 5.3212.76 ± 4.960.683
Early therapeutic regimen
Reduced glutathione37 (100)17 (100)NA
Ademetionine37 (100)17 (100)NA
Diuretics37 (100)17 (100)NA
Low molecular weight heparin37 (100)17 (100)NA
Glucocorticoids11 (29.73)6 (35.29)0.757
Antibacterial drugs,23 (62.16)12 (70.60)0.549
Clinical symptoms on admission
Ascites (yes/no)37/017/0NA
Hepatomegaly (yes/no)26/1110/70.407
Hepatalgia (yes/no)15/227/100.965
Peritonitis (yes/no)7/302/150.512
Loss of appetite (yes/no)34/315/20.667
Gastrointestinal bleeding (yes/no)1/360/170.494
Weight gain (yes/no)12/256/110.836
Laboratory indicators at 2 wk
Total bilirubin (μmol/L)53.3 (39.8)53.6 (45.0)0.904
Direct bilirubin (μmol/L)32.4 (32.6)37.4 (47.0)0.520
Alanine transaminase (U/L)45.0 (69.0)55.0 (86.0)0.342
Aspartate transaminase (U/L)65.0 (48.0)62.0 (89.0)0.628
Gamma-glutamyl transferase (U/L)125.0 (90.0)91.0 (94.0)0.099
Alkaline phosphatase (U/L)112.6 (60.0)95.0 (91.0)0.087
Albumin (g/L)31.32 ± 3.3831.95 ± 4.920.588
Prothrombin time (s)15.81 ± 3.6416.75 ± 2.280.342
White blood cell count (109/L)6.75 ± 3.056.66 ± 2.200.913
Neutrophil proportion (%)64.19 ± 12.1664.39 ± 10.700.955
Red blood cell count (1012/L)4.91 ± 0.814.49 ± 0.630.064
Platelet count (109/L)108.0 (49.0)90.0 (68.0)0.165
Blood urea nitrogen (mmol/L)6.8 (3.4)5.6 (4.3)0.252
Creatinine (μmol/L)67.6 (32.0)75.0 (35.0)0.780
Maximum depth of ascites (mm)95.22 ± 22.5881.65 ± 26.290.057